Lastly, qRT-PCR was performed to confirm that CXCR2, NAMPT, and CUEDC2 could potentially serve as biomarkers for the clinical diagnosis and risk evaluation of DN patients. This evidence concerns the gene NAMPT and liver dysplastic nodule.